Oss, The Netherlands, March 6, 2015 / B3C newswire / - ModiQuest Research BV, the Dutch antibody services company, today announced that it has entered into a collaboration with Cellectis aimed at the generation of novel monoclonal antibodies against Cellectis’ target(s). During the collaboration, ModiQuest may make use of its proprietary electrofusion technology, ModiFuse™. Financial details of the collaboration were not disclosed.
“We are pleased that Cellectis has selected ModiQuest Research as a development partner for its activities,” said Dr. Jos Raats, Managing Director of ModiQuest Research. “This collaboration once more demonstrates the value of our broad and unique antibody generation platform and we are delighted to work together with Cellectis in the emerging field of cancer immunotherapy.”
About ModiQuest Research BV
Founded in 2005 and located in Oss (The Netherlands), ModiQuest Research is a Dutch biotechnology company that specializes in the generation of monoclonal antibodies against difficult target antigens. Using its proprietary ModiFuse™ (electrofusion hybridoma), ModiSelect™ (B-cell selection) and ModiPhage™ (phage display) technologies, ModiQuest Research can generate monoclonal antibodies from various backgrounds such as mouse, rat, rabbit, chicken, llama and human against virtually any target. Besides lead antibody generation, ModiQuest Research also provides antigen design, antibody optimization, production, processing and assay development. All services offered by ModiQuest Research are available on a fee-for-service basis.
Contact
Dr. Jos Raats
+31 412 846000
This email address is being protected from spambots. You need JavaScript enabled to view it.